The decrease in ER Ca2+ content has been linked to reduced SERCA activity44,50,51 and Ca2+ leakage through the RyR2,10, offering a rationale for considering the repurposing of the established drug dantrolene as a potential treatment for WS by inhibiting RyR10,52. This evidence concerns the gene RYR2 and Werner syndrome.